

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

**POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE AGM
THE 2025 FIRST A SHAREHOLDERS' CLASS MEETING AND
THE 2025 FIRST H SHAREHOLDERS' CLASS MEETING
RE-ELECTION AND ELECTION OF DIRECTORS
CANCELLATION OF SUPERVISORY COMMITTEE AND RETIREMENT OF
SUPERVISORS
DISTRIBUTION OF FINAL DIVIDEND
AND
CLOSURE OF REGISTER OF MEMBERS FOR H SHARES**

The annual general meeting (the “**AGM**”), the 2025 first class meeting of holders of A shares of the Company (the “**A Shareholders' Class Meeting**”) and the 2025 first class meeting of holders of H shares of the Company (the “**H Shareholders' Class Meeting**”) (collectively, the “**Meetings**”) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) were held in such order at Sky Fortune Boutique Hotel Shanghai No. 358 Hong Xu Road, Shanghai, the PRC on Tuesday, 24 June 2025 from 1:30 p.m.

References are made to the notice of the AGM, the notice of the H Shareholders' Class Meeting and the circular (the “**Circular**”) of the Company, all dated 20 May 2025. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the record dates of the Meetings, (i) the total number of the issued shares of the Company (the “**Shares**”) was 2,670,429,325 Shares, comprising 2,118,488,825 A Shares and 551,940,500 H Shares; (ii) holders of 2,643,122,273 Shares (or by authorised proxies) were entitled to attend and vote on the resolutions proposed at the AGM; and (iii) holders of 2,101,831,773 A Shares (or by authorised proxies) and 541,290,500 H Shares (or by authorised proxies) were entitled to attend and vote on the resolutions at the A Shareholders' Class Meeting and H Shareholders' Class Meeting, respectively. There were no Shares entitling the Shareholders to attend and vote only against the resolutions at the Meetings.

Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong (who held an aggregate of 1,487,778 A Shares and 438,000 H Shares as at the record date of the AGM) were required to and had abstained from voting at the AGM on the resolution in relation to the appraisal results and remunerations of Directors (i.e. resolution no. 6 below). Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Wu Yifang (who held an aggregate of 1,621,778 A Shares and 458,000 H Shares as at the record date of the AGM) were required to and had abstained from voting at the AGM on the resolution in relation to the appraisal program of Directors (i.e. resolution no. 7 below). To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, save as disclosed above, no other Shareholder has any material interest in the resolutions proposed at the AGM, the A Shareholders' Class Meeting or the H Shareholders' Class Meeting and is required to abstain from voting at the AGM, the A Shareholders' Class Meeting or the H Shareholders' Class Meeting. No Shareholder has stated in the Circular his/her/its intention to vote against any resolution at the Meetings.

ATTENDANCE AT THE MEETINGS

(I) Attendance at the AGM:

Set out below are the details of the Shareholders and authorised proxies present at the AGM:

Number of Shareholders and authorised proxies	1,299
<i>Including:</i> Number of A Shareholders	1,298
Number of H Shareholders	1
Total number of Shares carrying voting rights (shares)	1,043,791,203
<i>Including:</i> Total number of Shares carrying voting rights held by A Shareholders (shares)	940,830,290
Total number of Shares carrying voting rights held by H Shareholders (shares)	102,960,913
Percentage of the total number of Shares carrying voting rights (%)	39.4908
<i>Including:</i> Number of A Shares as a percentage of the total number of Shares carrying voting rights (%)	35.5954
Number of H Shares as a percentage of the total number of Shares carrying voting rights (%)	3.8954

(II) Attendance at the A Shareholders' Class Meeting:

Set out below are the details of the A Shareholders and authorised proxies present at the A Shareholders' Class Meeting:

Number of A Shareholders and authorised proxies	1,298
Total number of A Shares carrying voting rights (shares)	940,830,290
Number of A Shares as a percentage of the total number of A Shares carrying voting rights of the Company (%)	44.7624

(III) Attendance at the H Shareholders' Class Meeting:

Set out below are the details of the H Shareholders and authorised proxies present at the H Shareholders' Class Meeting:

Number of H Shareholders and authorised proxies	1
Total number of H Shares carrying voting rights (shares)	107,137,467
Number of H Shares as a percentage of the total number of H Shares carrying voting rights of the Company (%)	19.7930

The Meetings were convened in compliance with the requirements of the Company Law and the Articles of Association, and was chaired by Mr. Chen Yuqing, the chairman of the Board of the Company. Eleven (11) Directors of the ninth session of the Board of the Company attended the Meetings, including four (4) executive Directors, namely Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong and Mr. Wang Kexin; three (3) non-executive Directors, namely Mr. Chen Qiyu, Mr. Pan Donghui and Mr. Wu Yifang; and four (4) independent non-executive Directors, namely Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

In compliance with the requirements of the Hong Kong Listing Rules and Article 105 of the Articles of Association then in force, BDO Limited, Grandall Law Firm (Shanghai)* (國浩律師(上海)事務所), the Company's PRC legal advisers, Shareholder's representatives and member(s) of the ninth session of the Supervisory Committee of the Company acted as the scrutineers for the vote-counting at each of the Meetings.

Note regarding the scope of work of BDO Limited: The poll results were subject to scrutiny by BDO Limited, Certified Public Accountants (Practising), whose work was limited to certain procedures requested by the Company to agree the poll results summary prepared by the Company to poll forms collected and provided by the Company to BDO Limited. The work performed by BDO Limited in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants nor did it include provision of any assurance or advice on matters of legal interpretation or entitlement to vote.

POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE MEETINGS

(I) Poll results of the AGM:

All resolutions at the AGM were voted on by poll. The poll results in respect of the resolutions proposed at the AGM are as follows:

ORDINARY RESOLUTIONS		Number of valid votes		
		For	Against	Abstain
1.	To consider and, if thought fit, approve the annual report of the Group for the year 2024.	1,040,326,243 (99.6680%)	3,220,260 (0.3085%)	244,700 (0.0235%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
2.	To consider and, if thought fit, approve the work report of the Board for the year 2024.	1,040,237,043 (99.6604%)	3,299,760 (0.3161%)	244,400 (0.0235%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
3.	To consider and, if thought fit, approve the work report of the Supervisory Committee for the year 2024.	1,040,319,343 (99.6683%)	3,228,760 (0.3093%)	233,100 (0.0224%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
4.	To consider and, if thought fit, approve the profit distribution proposal of the Company for the year 2024.	1,040,468,843 (99.6827%)	3,125,360 (0.2994%)	187,000 (0.0179%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
5.	To consider and, if thought fit, approve the re-appointment of Ernst & Young Hua Ming LLP as the PRC financial report and internal control report auditors of the Company for the year 2025 and re-appointment of Ernst & Young as international financial report auditors of the Company for the year 2025 and the passing of remuneration packages for the PRC and international auditors for the year 2024.	1,039,894,597 (99.6276%)	3,681,106 (0.3527%)	205,500 (0.0197%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			

ORDINARY RESOLUTIONS		Number of valid votes		
		For	Against	Abstain
6.	To consider and, if thought fit, approve the appraisal results and remunerations of Directors for 2024.	1,039,998,064 (99.6376%)	3,551,639 (0.3403%)	231,500 (0.0221%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
7.	To consider and, if thought fit, approve the appraisal program of Directors for 2025.	1,040,134,364 (99.6506%)	3,435,639 (0.3292%)	211,200 (0.0202%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
8.	To consider and, if thought fit, approve the renewed and additional entrusted loans/borrowings quota of the Group.	1,038,805,085 (99.5233%)	4,608,118 (0.4415%)	368,000 (0.0352%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
9.	To consider and, if thought fit, approve the additional total credit applications of the Company.	1,038,949,207 (99.5371%)	4,473,396 (0.4286%)	358,600 (0.0343%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
10.	To consider and, if thought fit, approve the authorisation of the management to dispose of the shares of the listed companies held by the Group.	1,040,375,344 (99.6727%)	3,112,459 (0.2982%)	303,400 (0.0291%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
11.	To consider and, if thought fit, approve the proposed grant of general mandate to register and issue corporate bonds.	1,039,160,286 (99.5563%)	4,282,217 (0.4103%)	348,700 (0.0334%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
12.	To consider and, if thought fit, approve the amendments to the Management System for Proceeds of the Company.	1,040,302,143 (99.6657%)	3,211,060 (0.3076%)	278,000 (0.0267%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
13.	To consider and, if thought fit, approve the amendments to the Related Party Transaction Management System of the Company.	1,040,335,143 (99.6689%)	3,190,760 (0.3057%)	265,300 (0.0254%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			

ORDINARY RESOLUTIONS		Number of valid votes		
		For	Against	Abstain
14.	To consider and, if thought fit, approve the amendments to the Implementation Rules of Cumulative Voting System of the Company.	1,040,352,143 (99.6705%)	3,181,960 (0.3048%)	257,100 (0.0247%)
As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.				
15.	To consider and, if thought fit, approve the formulation of the Administrative Measures for Co-investment of the Company.	1,040,332,743 (99.6687%)	3,203,860 (0.3069%)	254,600 (0.0244%)
As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.				

SPECIAL RESOLUTIONS		Number of valid votes		
		For	Against	Abstain
16.	To consider and, if thought fit, approve the renewed and additional guarantee quota of the Group.	1,038,768,986 (99.5188%)	4,583,617 (0.4391%)	438,600 (0.0421%)
As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.				
17.	To consider and, if thought fit, approve the proposed grant of general mandate to issue A Shares and/or H Shares.	1,018,058,788 (97.5347%)	25,440,515 (2.4373%)	291,900 (0.0280%)
As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.				
18.	To consider and, if thought fit, approve the proposed grant of general mandate to repurchase H Shares.	1,040,622,144 (99.6964%)	2,958,559 (0.2834%)	210,500 (0.0202%)
As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.				
19.	To consider and, if thought fit, approve the proposed grant of general mandate to repurchase A Shares.	1,040,715,644 (99.7053%)	2,892,059 (0.2771%)	183,500 (0.0176%)
As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.				
20.	To consider and, if thought fit, approve the proposed cancellation of the Supervisory Committee and amendments to the Articles of Association and its Appendices.	1,036,238,009 (99.2773%)	7,318,694 (0.7012%)	224,500 (0.0215%)
As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.				

ORDINARY RESOLUTIONS		Number of valid votes
21.	To elect the executive Directors and non-executive Directors of the tenth session of the Board (by cumulative voting) :	
21(a).	To elect Mr. Chen Yuqing as an executive Director.	1,036,675,510 (99.3183%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.	
21(b).	To elect Ms. Guan Xiaohui as an executive Director.	1,035,901,725 (99.2442%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.	
21(c).	To elect Mr. Wen Deyong as an executive Director.	1,035,564,768 (99.2119%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.	
21(d).	To elect Mr. Wang Kexin as an executive Director.	1,035,700,397 (99.2249%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.	
21(e).	To elect Mr. Chen Qiyu as a non-executive Director.	1,025,582,711 (98.2555%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.	
21(f).	To elect Mr. Pan Donghui as a non-executive Director.	1,029,724,197 (98.6523%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.	
21(g).	To elect Mr. Wu Yifang as a non-executive Director.	1,032,459,329 (98.9144%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.	
22.	To elect the independent non-executive Directors of the tenth session of the Board (by cumulative voting):	
22(a).	To elect Mr. Wang Quandi as an independent non-executive Director	1,029,317,393 (98.6133%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.	

ORDINARY RESOLUTIONS		Number of valid votes	
22(b).	To elect Mr. Yu Tze Shan Hailson as an independent non-executive Director.	1,036,865,889 (99.3365%)	
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.		
22(c).	To elect Mr. Yang Yucheng as an independent non-executive Director.	1,036,962,702 (99.3458%)	
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.		
22(d).	To elect Mr. Chen Penghui as an independent non-executive Director.	1,037,823,186 (99.4282%)	
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.		

(II) Poll results of the A Shareholders' Class Meeting:

The resolutions proposed at the A Shareholders' Class Meeting were voted on by poll. The poll results in respect of the resolutions proposed at the A Shareholders' Class Meeting are as follows:

SPECIAL RESOLUTIONS		Number of valid votes		
		For	Against	Abstain
1.	To consider and, if thought fit, approve the proposed grant of general mandate to repurchase H Shares.	937,671,231 (99.6642%)	2,948,559 (0.3134%)	210,500 (0.0224%)
	As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.			
2.	To consider and, if thought fit, approve the proposed grant of general mandate to repurchase A Shares.	937,764,731 (99.6742%)	2,882,059 (0.3063%)	183,500 (0.0195%)
	As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.			
3.	To consider and, if thought fit, approve the proposed cancellation of the Supervisory Committee and amendments to the Articles of Association and its Appendices.	933,300,796 (99.1997%)	7,304,994 (0.7764%)	224,500 (0.0239%)
	As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.			

(III) Poll results of the H Shareholders' Class Meeting:

The resolutions proposed at the H Shareholders' Class Meeting were voted on by poll. The poll results in respect of the resolutions proposed at the H Shareholders' Class Meeting are as follows:

SPECIAL RESOLUTIONS		Number of valid votes		
		For	Against	Abstain
1.	To consider and, if thought fit, approve the proposed grant of general mandate to repurchase the H Shares.	107,127,467 (99.9907%)	10,000 (0.0093%)	0 (0.0000%)
	As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.			
2.	To consider and, if thought fit, approve the proposed grant of general mandate to repurchase the A Shares.	107,127,467 (99.9907%)	10,000 (0.0093%)	0 (0.0000%)
	As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.			
3.	To consider and, if thought fit, approve the proposed cancellation of the Supervisory Committee and amendments to the Articles of Association and its Appendices.	106,662,068 (99.5563%)	475,379 (0.4436%)	20 (0.0001%)
	As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.			

CERTIFICATION

As certified by and stated in the legal opinion issued by Grandall Law Firm (Shanghai)* (國浩律師(上海)事務所), the Company's PRC legal advisers, the convening and holding of the Meetings are in compliance with requirements of the relevant laws, administrative regulations, the Rules of General Meetings of Listed Companies and the Articles of Association, the qualifications of the attendees of the Meetings and the convener are legally valid, and the voting procedures and voting results of the Meetings are legally valid.

RE-ELECTION AND ELECTION OF DIRECTORS

At the AGM, Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong and Mr. Wang Kexin were respectively and duly re-elected by the Shareholders as the executive Directors of the tenth session of the Board. Mr. Chen Qiyu, Mr. Pan Donghui and Mr. WuYifang were respectively and duly re-elected by the Shareholders as the non-executive Directors of the tenth session of the Board. Mr. Yu Tze Shan Hailson and Mr. Wang Quandi were respectively and duly re-elected by the Shareholders as the independent non-executive Directors of the tenth session of the Board. Mr. Chen Penghui and Mr. Yang Yucheng were respectively and duly elected by the Shareholders as the independent non-executive Directors of the tenth session of the Board. The aforementioned Directors re-elected and elected at the AGM, together with Ms. Yan Jia, an employee Director elected at the employee representative meeting of the Company, jointly form the tenth session of the Board.

The appointment of the members of the tenth session of the Board shall be effective from 24 June 2025, and the term of office of the Directors shall be three years (except for independent non-executive Directors who have served for six years and are due for retirement).

The biographical details of the newly appointed Directors, Mr. Cheng Penghui, Mr. Yang Yucheng and Ms. Yan Jia are as follows:

(I) Mr. Chen Penghui

Mr. Chen Penghui, aged 53, is currently an independent non-executive Director of the Company. Mr. Chen Penghui is a founding partner of Borui Yuye (Shanghai) Equity Investment Management Co., Ltd.* (博睿瑜業上海股權投資管理有限公司) and serves as a member of the investment management committee of several medical funds managed by such company. Mr. Chen Penghui has served as an independent non-executive director of VCREDIT Holdings Limited (stock code: 02003), a company listed on the Hong Kong Stock Exchange, since June 2018, and an independent director of Chengdu Bright Eye Hospital Group Co., Ltd.* (成都普瑞眼科醫院股份有限公司) (stock code: 301239), a company listed on the SZSE, since September 2019. Mr. Chen Penghui served as a researcher at Ligand Pharmaceuticals Incorporated (stock code: LGND), a United States biotechnology company listed on NASDAQ, engaging in new drug development, from May 1998 to August 2001; and an investment vice president of CITIC Capital Holdings Limited from March 2007 to June 2008; successively served as the chief operating officer, chief financial officer and president of ShangPharma Corporation (listed on the New York Stock Exchange in 2010 and delisted in 2013, stock code: SHP) from July 2008 to December 2011; the head of medical funds and managing director at China Everbright Limited from December 2011 to May 2014; a partner of Sequoia Capital China* (紅杉資本中國基金) from May 2014 to May 2017; a director of Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.* (江蘇魚躍醫療設備股份有限公司) (stock code: 002223), a company listed on the SZSE, from April 2015 to November 2017; a director of BGI Genomics Co., Ltd.* (深圳華大基因股份有限公司) (stock code: 300676), a company listed on the SZSE, from June 2015 to June 2021; and an independent non-executive director of Hygeia Healthcare Holdings Co., Limited (stock code: 06078), a company listed on the Hong Kong Stock Exchange, from September 2019 to May 2022. Mr. Chen Penghui obtained a bachelor's degree in chemistry from Nanjing University, a master's degree in medicinal chemistry from Tulane University in the United States, and a master's degree in business administration (MBA) from Kellogg School of Management of Northwestern University in the United States. Mr. Chen Penghui holds a China security investment fund practice certificate* (中國證券投資基金業從業證書). Mr. Chen Penghui is currently a deputy director of the Pharmaceutical Innovation Investment Specialty Committee of the China Pharmaceutical Innovation and Research Development Association* (中國醫藥創新促進會醫藥創新投資專業委員會) and a member of the Healthcare and Elderly Care Industry Investment Specialty Committee of the Insurance Asset Management Association of China* (中國保險資產管理業協會醫療健康和養老產業投資專業委員會).

The Company will enter into the relevant appointment letter with Mr. Chen Penghui for his appointment as an independent non-executive Director for a term of three years effective from 24 June 2025. Pursuant to the allowance policy approved by Shareholders at the Company's annual general meeting for the year of 2022, the allowance standard for independent non-executive Directors is RMB400,000 per year (before tax), to be paid based on the actual term of office.

Mr. Chen Penghui has confirmed that, save as disclosed above, as at the date of this announcement, he does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company, and does not hold any other positions in the Company or any of its subsidiaries nor any other directorships in listed public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years. As at the date of this announcement, Mr. Chen Penghui does not have any interests or short positions in any Shares, underlying shares or debentures of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, there is no other information in relation to Mr. Chen Penghui which is required to be disclosed pursuant to Rule 13.51(2) of the Hong Kong Listing Rules, nor are there other matters in relation to Mr. Chen Penghui that need to be brought to the attention of the Shareholders.

(II) Mr. Yang Yucheng

Mr. Yang Yucheng (楊玉成), aged 60, is currently an independent non-executive Director of the Company. Mr. Yang Yucheng is currently the chairman of the board of directors and the executive director of Shanghai Yiyuan Private Fund Management Co., Ltd.* (上海鈺遠私募基金管理有限公司) (“**Shanghai Yiyuan**”) and a vice director of the Shanghai Financial Professional Degree Graduate Education Guidance Committee* (上海市金融專業學位研究生教育指導委員會). Mr. Yang Yucheng served as a teaching assistant and lecturer at Shanghai University of Finance and Economics from July 1986 to July 1993; the head of the business department, a researcher, an assistant to the general manager of the securities investment department and the head of the marketing headquarter of Junan Securities Co., Ltd.* (君安證券有限責任公司) (currently renamed as Guotai Haitong Securities Co. Ltd.* (國泰海通證券股份有限公司) (stock codes: 601211 and 02611), a company listed on the SSE and the Hong Kong Stock Exchange) from August 1993 to January 1999; a deputy general manager, office director, board secretary and director of Shanghai Dazhong Enterprises of Science and Technology Ltd.* (上海大眾科技創業 (集團)股份有限公司), a company listed on the SSE (currently known as Shanghai Dazhong Public Utilities (Group) Co., Ltd.* (上海大眾公用事業 (集團)股份有限公司) and listed on the Hong Kong Stock Exchange in 2016 (stock codes: 600635 and 01635)) from February 1999 to July 2001; a director and deputy general manager of Shanghai Shenergy Asset Management Co., Ltd.* (上海申能資產管理有限公司) from October 2001 to June 2004; the chief financial officer and a vice president of Orient Securities Co., Ltd.* (東方證券股份有限公司) (“**Orient Securities**”) from July 2004 to June 2007; a director and the general manager of Shenergy Group Finance Co., Ltd.* (申能集團財務有限公司) from July 2007 to July 2009; a vice president of Orient Securities (stock codes: 600958 and 03958), a company listed on the SSE in 2015 and on the Hong Kong Stock Exchange in 2016, from August 2009 to May 2020, during which time he served as a board secretary of Orient Securities from January 2012 to November 2016 and as a joint company secretary of Oriental Securities from July 2016 to October 2019; the general manager of Shanghai

Securities Co., Ltd.* (上海證券有限責任公司) from July 2020 to November 2021; the chairman of the board of directors of Shanghai Commercial Investment (Group) Co., Ltd.* (上海市商業投資(集團)有限公司) from December 2021 to May 2022; and the head of administration of Shanghai Yisheng Investment Management Co., Ltd.* (上海弋盛投資管理有限公司) from June 2022 to March 2024; and has served as the chairman of the board of directors and an executive director of Shanghai Yiyuan from April 2024. Mr. Yang Yucheng obtained a bachelor's and a master's degree in economics from Shanghai University of Finance and Economics, as well as a doctor's degree in wealth management from the University of Geneva.

The Company will enter into the relevant appointment letter with Mr. Yang Yucheng for his appointment as an independent non-executive Director for a term of three years effective from 24 June 2025. Pursuant to the allowance policy approved by the Shareholders at the Company's annual general meeting for the year of 2022, the allowance standard for independent non-executive Directors is RMB400,000 per year (before tax), to be paid based on the actual term of office.

Mr. Yang Yucheng has confirmed that, save as disclosed above, as at the date of this announcement, he does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company, and does not hold any other positions in the Company or any of its subsidiaries nor any other directorships in listed public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years. As at the date of this announcement, Mr. Yang Yucheng does not have any interests or short positions in any Shares, underlying shares or debentures of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, there is no other information in relation to Mr. Yang Yucheng which is required to be disclosed pursuant to Rule 13.51(2) of the Hong Kong Listing Rules, nor are there other matters in relation to Mr. Yang Yucheng that need to be brought to the attention of the Shareholders.

(III) Ms. Yan Jia

Ms. Yan Jia (嚴佳), aged 44, is currently the employee Director, co-chief financial officer, assistant to the president, chief accountant, and chief financial officer of the innovative drug division of the Company, and she also serves as the director or supervisor in several subsidiaries of the Company. Ms. Yan Jia first joined the Group in March 2009, and successively served as a deputy director of financial audit, director of financial audit, deputy general manager of the financial department and accounting director of the Company from March 2009 to May 2017. In addition, Ms. Yan Jia served as the vice president and chief financial officer of the maternal & infant and family industry group of Fosun High Tech from June 2017 to April 2019. From May 2019 to March 2020, Ms. Yan Jia served as the director, chief financial officer and board secretary of Baihe Jiayuan Network Group Co., Ltd.* (百合佳緣網絡集團股份有限公司) (delisted from the National Equities Exchange and Quotations in December 2019, former stock code:834214), and from April 2020 to July 2020, she was the vice president and chief financial officer of the maternal & infant and family industry group of Fosun High Tech. Ms. Yan Jia rejoined the Group in August 2020. From August 2020 to June 2022, she successively served as the deputy general manager and accounting director, financial analysis director, and deputy chief financial officer of the financial department of the Company. Since June 2022, Ms.

Yan Jia served as the chief accountant, co-chief financial officer, and assistant to the president of the Company, and begun to hold the position of the chief financial officer of the innovative drug division of the Company since January 2025. In addition, Ms. Yan Jia served as a non-executive director of BabyTree Group (delisted from the Hong Kong Stock Exchange in December 2024, former stock code:01761) from June 2020 to January 2021, and as a supervisor of Anhui Sunhere Pharmaceutical Excipients Co., Ltd.* (安徽山河藥用輔料股份有限公司) (stock code: 300452), a company listed on the SZSE, from May 2021 to March 2024. Ms. Yan Jia obtained a bachelor of management in audit degree from Nanjing Audit College (currently known as Nanjing Audit University), and is a member of the Association of Chartered Certified Accountants (ACCA).

The Company will enter into the relevant appointment letter with Ms. Yan Jia for her appointment as the employee Director for a term of three years effective from 24 June 2025. Ms. Yan Jia will not receive any remuneration from the Group for her position as the employee Director.

Ms. Yan Jia has confirmed that, save as disclosed above, as at the date of this announcement, she does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company, and does not hold any other positions in the Company or any of its subsidiaries nor any other directorships in listed public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years. As at the date of this announcement, within the meaning of Part XV of the SFO, Ms. Yan Jia has personal interests in 6,271 Shares of the Company (all of which are A Shares), representing approximately 0.0002% of the total number of Shares of the Company (i.e. 2,670,429,325 Shares). Save as disclosed above, Ms. Yan Jia does not have any interests or short positions in any Shares, underlying shares or debentures of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, there is no other information in relation to Ms. Yan Jia which is required to be disclosed pursuant to Rule 13.51(2) of the Hong Kong Listing Rules, nor are there other matters in relation to Ms. Yan Jia that need to be brought to the attention of the Shareholders.

Information including the biographies, length of service and emolument of the nine (9) Directors re-elected at the AGM were set out in the Circular. As at the date of this announcement, save as disclosed in the Circular and this announcement, there is no other information in relation to such Directors which is required to be disclosed pursuant to Rule 13.51(2) of the Hong Kong Listing Rules, nor are there other matters in relation to their appointment that need to be brought to the attention of the Shareholders.

Each of Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng has confirmed (i) his independence as regards each of the factors referred to in Rules 3.13(1) to (8) of the Listing Rules; (ii) that he does not have any past or present financial or other interests in the business of the Company or its subsidiaries or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) that there are no other factors that may affect his independence at the time of his appointment.

CANCELLATION OF SUPERVISORY COMMITTEE AND RETIREMENT OF SUPERVISORS

As approved by the Shareholders at the Meetings, the Board hereby announces that the Supervisory Committee has been cancelled after the conclusion of the Meetings. Furthermore, Mr. Chen Bing, Mr. Guan Yimin and Ms. Wang Lina have retired as the Supervisors of the Company after the conclusion of the Meetings. Each of Mr. Chen Bing, Mr. Guan Yimin and Ms. Wang Lina has confirmed that there are no disagreements between him/her and the Supervisory Committee and/or the Company during his/her term of office and there are no matters relating to his/her retirement that need to be brought to the attention of the Shareholders.

The Company hereby expresses its gratitude to Mr. Chen Bing, Mr. Guan Yimin and Ms. Wang Lina for their valuable contribution during their terms of office.

DISTRIBUTION OF FINAL DIVIDEND AND CLOSURE OF REGISTER OF MEMBERS FOR H SHARES

As approved by the Shareholders at the AGM, the Board is pleased to announce that the final dividend to the Shareholders for the year ended 31 December 2024 of RMB0.32 per Share (before tax) from the undistributed profit of the Company to Shareholders who are qualified for participating in profit distribution. The 2024 final dividend will be paid to A Shareholders in RMB and to H Shareholders in Hong Kong dollars. The actual amount of the 2024 final dividend for H Shares to be paid in Hong Kong dollars shall be calculated with reference to the average benchmark exchange rate between RMB and Hong Kong dollars as published by the People's Bank of China for the five (5) business days preceding the date of the AGM (i.e. RMB0.91376 to HK\$1), being a cash dividend of HK\$0.35 per Share (before tax).

The 2024 final dividend for H shares will be paid to H Shareholders whose names are registered in the Company's register of members on Friday, 1 August 2025 (excluding any holder of treasury shares if any). For the purpose of determining the entitlement of Shareholders to the 2024 final dividend for H Shares, the register of members of the Company for H Shares will be closed from Monday, 28 July 2025 to Friday, 1 August 2025, both days inclusive. In order to qualify for the 2024 final dividend for H Shares, unregistered H Shareholders of the Company should ensure that all transfer documents for H Shares together with the relevant share certificates should be lodged for registration with the Company's Hong Kong share registrar for H Shares, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 4:30 p.m. on Friday, 25 July 2025.

According to the requirements of the Enterprise Income Tax Law of the PRC effective from 1 January 2008 and the implementation rules thereof, the Decision of the Standing Committee of the National People's Congress on Amending the Enterprise Income Tax Law of the PRC (《全國人民代表大會常務委員會關於修改〈中華人民共和國企業所得稅法〉的決定》) effective from 24 February 2017 and the Notice on the Issues Concerning Withholding the Enterprise Income Tax on the Dividends Paid by Chinese Resident Enterprises to H Share Holders which are Overseas Non-resident Enterprises (Guo Shui Han [2008] No. 897) (《關於中國居民企業向境外H股非居民企業股東派發股息代扣代繳企業所得稅有關問題的通知》(國稅函 [2008] 897號)) issued by the State Administration of Taxation on 6

November 2008, the 2024 final dividend payable to the non-resident enterprise shareholders whose names appear on the registers of members of H Shares is subject to a withholding tax at a rate of 10%. Any shares registered in the name of the non-individual registered shareholders, including HKSCC Nominees Limited, other nominees or trustees and other organizations and groups will be treated as being held by non-resident enterprise shareholders and therefore will be subject to the withholding of the enterprise income tax of 10%.

According to the Notice on Matters Concerning the Levy and Administration of Individual Income Tax after the Repeal of Guo Shui Fa[1993]No. 045 (Guo Shui Han [2011] No. 348) (《關於國稅發[1993]045號文件廢止後有關個人所得稅徵管問題的通知》(國稅函 [2011] 348號)) issued by the State Administration of Taxation on 28 June 2011 and the Letter on the Tax Arrangements on Dividends Paid to Hong Kong Residents by Mainland Companies issued by the Hong Kong Stock Exchange on 4 July 2011, when domestic companies other than foreign invested enterprises which issue shares in Hong Kong distribute dividends to their shareholders, the individual shareholders in general will be subject to an individual withholding tax at a rate of 10%. When the Company distributes the 2024 final dividend to all individual holders of H Shares whose names appear on the registers of members of H Shares on Friday, 1 August 2025, the 2024 final dividend will be subject to the individual withholding tax at a rate of 10%. However, if otherwise provided by tax laws and regulations, relevant tax treaties or notices, the tax will be withheld in accordance with the relevant requirements and tax levy and administration requirements.

Profit distribution for the Investors of Northbound Trading

For investors of the Hong Kong Stock Exchange (including enterprises and individuals) investing in the A Shares listed on the Shanghai Stock Exchange (the “**Northbound Trading**”), the 2024 final dividend will be distributed in RMB by the Company through the Shanghai Branch of China Securities Depository and Clearing Corporation Limited to the nominee account holding such Shares. The Company will withhold and pay income taxes at the rate of 10% on behalf of those investors and will report to the tax authorities for the withholding. For investors of Northbound Trading who are tax residents of other countries and whose country of domicile is a country which has entered into a tax treaty with the PRC stipulating a dividend tax rate of lower than 10%, those enterprises and individuals may, or may authorise a withholding agent to, apply to the competent tax authorities governing the Company for the entitlement of the rate under such tax treaty. Upon approval by the tax authorities, the paid amount in excess of the tax payable based on the tax rate according to such tax treaty will be refunded.

The record date and the date of distribution of cash dividends and other arrangements for the investors of Northbound Trading will be the same as those for the A Shareholders.

Profit distribution for the Investors of Southbound Trading

For investors of the Shanghai Stock Exchange and Shenzhen Stock Exchange (including enterprises and individuals) investing in the H Shares listed on the Hong Kong Stock Exchange (the “**Southbound Trading**”), the cash dividends for investors of Southbound Trading will be paid in RMB. The record

date and the date of distribution of cash dividends and other arrangements for the investors of Southbound Trading will be the same as those for the H Shareholders. The relevant taxation policies are set out below:

Shanghai-Hong Kong Stock Connect: the Shanghai Branch of China Securities Depository and Clearing Corporation Limited, as the nominee of the investors of H Shares for Shanghai-Hong Kong Stock Connect, will receive the cash dividends distributed by the Company and distribute the cash dividends to the relevant investors of H Shares of Shanghai-Hong Kong Stock Connect through its depository and clearing system. Pursuant to the Notice on the Tax Policies Related to the Pilot Program of the Shanghai-Hong Kong Stock Connect (《關於滬港股票市場交易互聯互通機制試點有關稅收政策的通知》) (Caishui [2014] No. 81), for dividends received by mainland investors from investing in H shares listed on the Hong Kong Stock Exchange through Shanghai-Hong Kong Stock Connect, the company of such H shares shall withhold and pay individual income tax at the rate of 20% on behalf of the investors. For dividends received by mainland securities investment funds from investing in H shares listed on the Hong Kong Stock Exchange through Shanghai-Hong Kong Stock Connect, the tax payable shall be the same as that for individual investors. The company of such H shares will not withhold or pay the income tax of dividends for mainland enterprise investors and those enterprise investors shall report and pay the relevant tax themselves.

Shenzhen-Hong Kong Stock Connect: the Shenzhen Branch of China Securities Depository and Clearing Corporation Limited, as the nominee of the investors of H Shares for Shenzhen-Hong Kong Stock Connect, will receive the cash dividends distributed by the Company and distribute the cash dividends to the relevant investors of H Shares of Shenzhen-Hong Kong Stock Connect through its depository and clearing system. Pursuant to the Notice on the Tax Policies Related to the Pilot Program of the Shenzhen-Hong Kong Stock Connect (《關於深港股票市場交易互聯互通機制試點有關稅收政策的通知》) (Caishui [2016] No. 127), for dividends received by mainland investors from investing in H shares listed on the Hong Kong Stock Exchange through Shenzhen-Hong Kong Stock Connect, the company of such H shares shall withhold and pay individual income tax at the rate of 20% on behalf of the investors. For dividends received by mainland securities investment funds from investing in H shares listed on the Hong Kong Stock Exchange through Shenzhen-Hong Kong Stock Connect, the tax payable shall be the same as that for individual investors. The company of such H shares will not withhold or pay the income tax of dividends for mainland enterprise investors and those enterprise investors shall report and pay the relevant tax themselves.

The Company will withhold the income tax payable by its H Shareholders in accordance with the relevant laws and requirements of the relevant government departments and adhere strictly to the information set out in the Company's register of members for H Shares on the relevant record date. The Company assumes no liability whatsoever in respect of any disputes or losses arising from any delay in, or inaccurate determination of, the status of the Shareholders.

Shareholders are recommended to consult their tax advisers regarding the PRC, Hong Kong and other tax implications arising from their holding and disposal of H Shares.

The Company has appointed CMB Wing Lung Bank Limited as the receiving agent (the “**Receiving Agent**”) in Hong Kong and will pay the Receiving Agent the 2024 final dividend declared in respect of the H Shares, which will be held by the Receiving Agent on trust pending payment to the relevant H Shareholders. The 2024 final dividend for H Shares (net of applicable taxes) will be paid by the Receiving Agent and the relevant cheques will be mailed by Tricor Investor Services Limited on or around Friday, 22 August 2025 to the holders of the H Shareholders whose names are registered in the Company’s register of members on Friday, 1 August 2025 by ordinary post at their own risk.

An announcement regarding the details of the distribution of 2024 final dividend for A Shares will be published on the website of the Shanghai Stock Exchange (<https://www.sse.com.cn>) for A Shareholders’ information.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
24 June 2025

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong and Mr. Wang Kexin; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Pan Donghui and Mr. Wu Yifang; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* *For identification purposes only*